Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: A 10-year, nationwide retrospective cohort study in taiwanese women

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1659-1667

  Hsiao, Fei Yuan ^a   Huang, Weng Foung ^b   Chen, Yi Ming ^b,c   Wen, Yu Wen ^d   Kao, Yu Hsiang ^b   Chen, Liang Kung ^b,e   Tsai, Yi Wen ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Alendronate; Antiosteoporosis drug; Atypical femoral fracture; Hip fracture; Osteoporosis; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; SALCATONIN;

AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; HIP FRACTURE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; RETROSPECTIVE STUDY; STROKE; TAIWAN;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; FEMALE; HIP FRACTURES; HUMANS; OSTEOPOROSIS; RETROSPECTIVE STUDIES; TAIWAN;

EID: 82855166071     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.006     Document Type: Article

References (25)

1. Bilezikian J.P. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009, 122:S14-S21.
2. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
3. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
4. Heckbert S.R., Li G., Cummings S.R., et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008, 168:826-831.
5. Feller L., Wood N.H., Khammissa R.A., et al. Bisphosphonate-related osteonecrosis of the jaw. SADJ 2011, 66:30-32.
6. Huang W.F., Tsai Y.W., Wen Y.W., et al. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause 2010, 17:57-63.
7. Mortensen M., Lawson W., Montazem A. Osteonecrosis of the jaw associated with bisphosphonate use: presentation of seven cases and literature review. Laryngoscope 2007, 117:30-34.
8. Cermak K., Shumelinsky F., Alexiou J., Gebhart M.J. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res 2010, 468:1991-1996.
9. Chan S.S., Rosenberg Z.S., Chan K., Capeci C. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. AJR Am J Roentgenol 2010, 194:1581-1586.
10. Kwek E.B., Goh S.K., Koh J.S., et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 2008, 39:224-231.
11. Nieves J.W., Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 2010, 8:34-39.
12. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
13. Abrahamsen B., Eiken P., Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010, 95:5258-5265.
14. Black D.M., Kelly M.P., Genant H.K., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771.
15. Hsiao F.Y., Yang C.L., Huang Y.T., Huang W.F. Using Taiwan national health insurance research databases for pharmacoepidemiology research. J Food Drug Anal 2007, 15:99-108.
16. National Health Insurance in Taiwan Bureau of National Health Insurance, Accessed July 20, 2011. http://www.nhi.gov.tw/english/index.asp.
17. Rosner B. Fundamentals of Biostatistics 2000, Duxbury Press, New York, NY. 5th ed.
18. Hosmer D.W., Lemeshow S., May S. Applied Survival Analysis: Regression Modeling of Time to Event Data 2008, Wiley-Interscience, New York, NY. 2nd ed.
19. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
20. Wells G.A., Cranney A., Peterson J., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008, 1. D001155.
21. Black D.M., Thompson D.E., Bauer D.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000, 85:4118-4124.
22. Recker R.R., Kendler D., Recknor C.P., et al. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 2007, 40:843-851.
23. Sambrook P.N., Geusens P., Ribot C., et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004, 255:503-511.
24. Armamento-Villareal R., Napoli N., Diemer K., et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009, 85:37-44.
25. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.